Sangamo Partners With CHDI

4/5/11Follow @xconomy

Sangamo Biosciences (NASDAQ: SGMO), the Richmond, CA-based drug developer, said today it has formed a collaboration with the New York-based CHDI Foundation to develop a new treatment for Huntington’s disease. Sangamo will use its targeted zinc-finger protein technology to aim at a gene that causes Huntington’s. Financial terms of the partnership weren’t disclosed.

By posting a comment, you agree to our terms and conditions.